Pipeline Perspectives: Peripheral Artery Disease Poor disease awareness hinders new agents

Table of Contents

• ABOUT DATAMONITOR HEALTHCARE
  • About the Disease pharmaceutical analysis team
• CHAPTER 1 EXECUTIVE SUMMARY
  • Scope of the analysis
  • Datamonitor insight into the PAD market
  • Key metrics
  • Datamonitor Pipeline Assessment Summary
• CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS
  • Pipeline overview
  • The PAD pipeline shows diverse mechanisms of action
  • The PAD pipeline is rich in Phase II candidates
  • Numerous companies have their stake in the R&D landscape
  • Key companies involved in the PAD pipeline
  • Key R&D company strategies
    • PAD as a secondary indication
    • Identifying suitable patient groups
• CHAPTER 3 Peripheral artery disease - MARKET POTENTIAL
  • Definition of Peripheral Artery Disease
    • Intermittent claudication
    • Critical Limb Ischemia
    • Consequences of PAD
  • Segmentation of PAD
  • Epidemiology of PAD
  • Forecasts of PAD
  • Unmet needs in PAD
    • Major obstacles between the drugs and the market
      • Patient awareness of PAD
      • Physician awareness of PAD
    • Clinical unmet needs
      • More treatment options required
      • Drugs trialed in patients with concomitant disease
      • Drugs with no / lower resistance
      • Drugs with greater efficacy
      • Ability to prevent cardiovascular events and amputations
      • More cost-effective care
      • Drugs with fewer side-effects
• CHAPTER 4 R&D APPROACH
  • Classification of pipeline products
    • Gene therapy
    • Antiplatelets
    • Thrombolytics
    • Prostaglandins
    • Others
  • Clinical trial design in PAD
    • Absolute claudication distance/initial claudication distance
    • Ankle to brachial index
    • Imaging
      • Pulse volume recording waveform analysis
      • Duplex arterial imaging or ultrasound imaging
      • Angiography
    • Improvement in symptoms and quality of life
    • Long-term morbidity and mortality
    • Potential areas for improvement in the clinical trial design
      • Trialing of new agents in specific patient subsets
      • Size of clinical trials
      • Outcome trials
• CHAPTER 5 ANTIPLATELETS LATE-STAGE DRUG ANALYSIS & FORECASTS
  • Overview for antiplatelets
    • Pipeline summary
    • Definition of current comparator therapy
  • Parogrelil (INDI-702)
    • Drug overview
    • Clinical trial data
    • Patient potential
    • Marketing factors
      • Conduct more trials on efficacy and resistance
    • Satisfaction of unmet needs
    • Forecasts to 2016
    • Datamonitor drug assessment summary
• CHAPTER 6 PROSTAGLANDINS LATE-STAGE DRUG ANALYSIS & FORECASTS
  • Overview for prostaglandins
    • Pipeline summary
    • Definition of current comparator therapy - Prostavasin
  • Liprostin (liposomal prostaglandin E-1, Endovasc)
    • Drug overview
    • Clinical trial data
    • Patient potential
    • Marketing factors
    • Satisfaction of unmet needs
    • Forecasts to 2016
    • Datamonitor drug assessment summary
• BIBLIOGRAPHY
  • Epidemiology
  • Clinical trial data and other
• APPENDIX A
  • Methodology
    • Datamonitor forecast methodology
      • Epidemiology forecasts
      • Product forecasts
• APPENDIX B
  • About Datamonitor
    • About Datamonitor Healthcare
  • Datamonitor Healthcare' s therapy area capabilities
    • About the Disease analysis team
    • Disclaimer
  • List of Tables
    • Table 1: Forecast prevalence of PAD (excluding borderline PAD) in the seven major markets (000), 2007-2016
    • Table 2: R&D pipeline for the treatment of PAD, 2007
    • Table 3: PAD pipeline by company, 2007
    • Table 4: Fontaine classification system for PAD
    • Table 5: Rutherford' s classification of PAD
    • Table 6: Forecast prevalence of PAD (excluding borderline PAD) in the seven major markets (000), 2007-2016
    • Table 7: PAD pipeline agents by drug class
    • Table 8: Antiplatelets for the treatment of PAD
    • Table 9: Otsuka and Pfizer' s Pletal: key facts
    • Table 10: Ability of parogrelil to satisfy the unmet needs, 2007
    • Table 11: Prostaglandins for the treatment of PAD
    • Table 12: Prostavasin: key facts
    • Table 13: Ability of Liprostin to satisfy the unmet needs, 2007
    • Table 14: Forecast prevalence of PAD (including borderline PAD) in the seven major markets (000), 2007-2016
    • Table 15: Datamonitor drug assessment parameters
  • List of Figures
    • Figure 1: Sales forecasts for antiplatelets, 7 major markets, 2007-16
    • Figure 2: Sales forecasts for prostaglandins, 7 major markets, 2007-16
    • Figure 3: Datamonitor drug assessment summary of antiplatelets in development for PAD, 2007
    • Figure 4: Datamonitor drug assessment summary of prostaglandins in development for PAD, 2007
    • Figure 5: R&D Pipeline for PAD agents, 2007
    • Figure 6: Main classes of agents in development for PAD, 2007
    • Figure 7: Percentage of R&D products in each Phase of development for PAD, 2007
    • Figure 8: Breakdown of PAD population
    • Figure 9: The most important unmet needs in PAD, 2007
    • Figure 10: Datamonitor drug assessment summary of antiplatelets in development for PAD, 2007
    • Figure 11: The percent mean improvement in maximal walking distance in trials with cilostazol
    • Figure 12: Sales forecast for parogrelil in PAD to 2016, seven major markets
    • Figure 13: Datamonitor' s competitive positioning analysis of parogrelil, 2007
    • Figure 14: Datamonitor drug assessment summary of prostaglandins in development for PAD, 2007
    • Figure 15: Sales forecast for Liprostin in PAD to 2016, seven major markets
    • Figure 16: Datamonitor' s competitive positioning analysis of Liprostin, 2007
    • Figure 17: Datamonitor drug assessment summary of pipeline molecular targeted therapies in development for hematological malignancies, 2007